By Dr. Gabriela Lenarczyk Dr. Lenarczyk is a 2024-2025 Edison Fellow. This blog post is in partial fulfillment of obligations for the Thomas Edison Innovation Law and Policy Fellowship. Recently resurfaced in U.S. politics, most-favored-nation (MFN) drug pricing is irresistible in its simplicity: If other wealthy countries pay less for the same medicines, why shouldn’t Medicare […]